Jefferies Group LLC reiterated their hold rating on shares of Hikma Pharmaceuticals Plc (LON:HIK) in a report published on Thursday morning. They currently have a GBX 1,045 ($13.74) price objective on the stock.
Several other analysts also recently weighed in on HIK. Morgan Stanley downgraded Hikma Pharmaceuticals Plc to an equal weight rating and dropped their price target for the company from GBX 2,050 ($26.96) to GBX 1,600 ($21.04) in a research note on Wednesday, August 2nd. Numis Securities Ltd reissued an add rating and issued a GBX 1,560 ($20.52) price objective on shares of Hikma Pharmaceuticals Plc in a report on Friday, August 11th. Peel Hunt reissued a hold rating and issued a GBX 2,150 ($28.28) price objective on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 17th. Goldman Sachs Group, Inc. (The) cut Hikma Pharmaceuticals Plc to a neutral rating and decreased their price objective for the company from GBX 2,600 ($34.20) to GBX 1,310 ($17.23) in a report on Tuesday, August 22nd. Finally, Citigroup Inc. reissued a neutral rating and issued a GBX 1,350 ($17.76) price objective on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. Hikma Pharmaceuticals Plc presently has an average rating of Hold and an average target price of GBX 1,321.91 ($17.39).
Hikma Pharmaceuticals Plc (LON HIK) traded down GBX 31.50 ($0.41) during trading on Thursday, reaching GBX 960.50 ($12.63). The company’s stock had a trading volume of 1,404,662 shares, compared to its average volume of 823,245. Hikma Pharmaceuticals Plc has a twelve month low of GBX 934 ($12.28) and a twelve month high of GBX 2,346 ($30.86).
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.